Last reviewed · How we verify
ibalizumab-uiyk
Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication.
Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication. Used for Treatment-experienced HIV-1 infection.
At a glance
| Generic name | ibalizumab-uiyk |
|---|---|
| Also known as | Trogarzo |
| Sponsor | TaiMed Biologics Inc. |
| Drug class | CD4 receptor antagonist |
| Target | CD4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
By binding to the CD4 receptor, ibalizumab-uiyk blocks the interaction between HIV and the host cell, thereby inhibiting viral entry and replication. This mechanism of action is specific to CD4-expressing cells, such as T cells, and is thought to be responsible for the drug's antiviral effects.
Approved indications
- Treatment-experienced HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Injection site reaction
Key clinical trials
- Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (PHASE1)
- CD4CAR for CD4+ Leukemia and Lymphoma (PHASE1)
- Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant (PHASE1)
- A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
- Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (PHASE1)
- External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ibalizumab-uiyk CI brief — competitive landscape report
- ibalizumab-uiyk updates RSS · CI watch RSS
- TaiMed Biologics Inc. portfolio CI